Efficacy of Zoledronic Acid in Maintaining Areal and Volumetric Bone Density After Combined Denosumab and Teriparatide Administration: DATA‐HD Study Extension

A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains

(2020) Judith Everts‐Graber et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial

(2020) Anne Sophie Sølling et al.   JOURNAL OF BONE AND MINERAL RESEARCH

The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis

(2020) Polyzois Makras et al.   BONE

Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS

(2020) Elena Tsourdi et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effect of Zoledronate on Bone Loss After Romosozumab/Denosumab: 2-Year Follow-up

(2019) Anne M. Horne et al.   CALCIFIED TISSUE INTERNATIONAL

Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2‐year Clinical Trial

(2019) Athanasios D. Anastasilakis et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Bone Mineral Density After Transitioning From Denosumab to Alendronate

(2019) David Kendler et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial

(2019) Joy N Tsai et al.   Lancet Diabetes & Endocrinology

Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo® Observational Study (ExFOS)

(2018) Nicola Napoli et al.   CALCIFIED TISSUE INTERNATIONAL

Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates

(2018) Anne M. Horne et al.   CALCIFIED TISSUE INTERNATIONAL

Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension

(2017) Steven R Cummings et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates

(2017) B. Uebelhart et al.   OSTEOPOROSIS INTERNATIONAL

Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures

(2017) T. Lehmann et al.   OSTEOPOROSIS INTERNATIONAL

Observations following discontinuation of long-term denosumab therapy

(2017) M. R. McClung et al.   OSTEOPOROSIS INTERNATIONAL

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates

(2016) P. D. Miller et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Denosumab versus zoledronic acid in patients previously treated with zoledronic acid

(2015) A. D. Anastasilakis et al.   OSTEOPOROSIS INTERNATIONAL

Simulated increases in body fat and errors in bone mineral density measurements by DXA and QCT

(2011) Elaine W Yu et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass

(2011) Henry G. Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of denosumab on bone turnover markers in postmenopausal osteoporosis

(2010) Richard Eastell et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial

(2010) Paul D. Miller et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of Teriparatide Treatment and Discontinuation in Postmenopausal Women and Eugonadal Men with Osteoporosis

(2009) Benjamin Z. Leder et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM